




Name	James Chih-Hsin Yang	
Country	Taiwan	
Organization	National Taiwan University Cancer Center	
Current Position	Director	

## Educational Background

National Taiwan University, School of Medicine	Bachelor of Medicine	Sep 1979 to June 1986
Graduate Institute of Clinical Medicine, National Taiwan University	Doctor of Philosophy	Sep 1996 to Jan 2000
National Taiwan University	Master of Executive Business Administration	Aug 2018 to Aug 2020

## Professional Experiences

Department of Medicine, National Taiwan University Hospital	Resident	July 1988 to June 1992
Medicine Branch, National Cancer Institute, National Institute of Health, USA	Exchange Scientist, Clinical Associate	July 1992 to Aug 1995
Department of Oncology, National Taiwan University Hospital	Attending physician	Sep 1995 till now (past deputy director and director)

## Professional Organizations

Graduate Institute of Oncology, Graduate Institute of Clinical Medicine Graduate Institute of Clinical Pharmacy National Taiwan University	Professor	Aug 2009 till now (As director, 2015- 2021) (As NTU chair professor, 2021-2024)
National Taiwan University Hospital	Director	Department of Medical Research 2013-2016
National Taiwan University Hospital	Director	Department of Oncology, 2015-2 020
National Taiwan University	Director	Graduate Institute of Oncology
National Taiwan University Cancer Center	Director Superintendent	Aug 2020 till now



## Main Scientific Publications

1. **Yang JC\***, Lee DH, Lee JS, Fan Y, de Marinis F, Iwama E, Inoue T, Rodríguez-Cid J, Zhang L, Yang CT, de la Mora Jimenez E, Zhou J, Pérol M, Lee KH, Vicente D, Ichihara E, Riely GJ, Luo Y, Chirovsky D, Pietanza MC, Bhagwati N, Lu S. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor-Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer **J Clin Oncol**. 2024 Aug 22: JCO2302747. doi: 10.1200/JCO.23.02747. Online ahead of print. PMID: 39173098(\***Corresponding Author**)
2. **Yang JC\***, Han B, De La Mora Jiménez E, Lee JS, Koralewski P, Karadurmus N, Sugawara S, Livi L, Basappa NS, Quantin X, Dudnik J, Ortiz DM, Mekhail T, Okpara CE, Dutcus C, Zimmer Z, Samkari A, Bhagwati N, Csósz T. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. **J Thorac Oncol**. 2024 Jun;19(6):941-953.. (\***Corresponding Author**)
3. Felip E, Metro G, Soo RA, Wolf J, Solomon BJ, Tan DS, Ardizzoni A, Lee DH, Sequist LV, Barlesi F, Ponce-Aix S, Abreu DR, Campelo MRG, Sprauten M, Djentuh LO, Smith N, Jary A, Belli R, Glaser S, Zou M, Cui X, Giovannini M, Yang JC. Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer **Eur J Cancer**. 2024 Sep;208:114182. doi: 10.1016/j.ejca.2024.114182. Epub 2024 Jun 22.
4. Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR, Wu YL, Gainor J, Lee SH, Chiu CH, Kim SW, Yang CT, Wu CL, Wu L, Lin MC, Samol J, Ichikado K, Wang M, Zhang X, Sylvester J, Li S, Forslund A, **Yang JC**. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. **J Clin Oncol**. 2024 Apr 10;42(11):1252-1264.
5. Jänne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, Laktionov K, Yang TY, Yu Y, Kato T, Jiang L, Chewaskulyong B, Lucien Geater S, Maurel JM, Rojas C, Takahashi T, Havel L, Shepherd FA, Tanaka K, Ghorghiu D, Amin NP, Armenteros-Monterroso E, Huang X, Chaudhry AA, **Yang JC**. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. **J Clin Oncol**. 2024 Mar 1;42(7):808-820.
6. **Yang JC**, Liu G, Lu S, He J, Burotto M, Ahn MJ, Kim DW, Liu X, Zhao Y, Vincent S, Yin J, Ma X, Lin HM, Popat S. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. **J Thorac Oncol**. 2023 Dec;18(12):1743-1755.
7. Wang M\*, **Yang JC\***, Mitchell PL, Fang J, Camidge DR, Nian W, Chiu CH, Zhou J, Zhao Y, Su WC, Yang TY, Zhu VW, Millward M, Fan Y, Huang WT, Cheng Y, Jiang L, Brungs D, Bazhenova L, Lee CK, Gao B, Xu Y, Hsu WH, Zheng L, Janne PA. Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations. **Cancer Discov**. 2022 Jul 6;12(7):1676-1689. (\***co-first author**)
8. Lu S, Wang Q, Zhang G, Dong X, Yang CT, Song Y, Chang GC, Lu Y, Pan H, Chiu CH, Wang Z, Feng J, Zhou J, Xu X, Guo R, Chen J, Yang H, Chen Y, Yu Z, Shiah HS, Wang CC, Yang N, Fang J, Wang P, Wang K, Hu Y, He J, Wang Z, Shi J, Chen S, Wu Q, Sun C, Li C, Wei H, Cheng Y, Su WC, Hsia TC, Cui J, Sun Y, Ou SI, Zhu VW, **Yang JC**. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. **J Thorac Oncol**. 2022 Mar;17(3):411-422.
9. **Yang JC\***, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, Chen J, Nikolinakos P, Lu Y, Pan H, Maniam A, Bazhenova L, Shirai K, Jahanzeb M, Willis M, Masood N, Chowhan N, Hsia TC, Jian H, Lu S. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. **J Thorac Oncol**. 2020 Dec;15(12):1907-1918. (\***Corresponding author**)
10. Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, John A, Scheele J, Park K, **Yang JC**. INSIGHT Investigators. Tepotinib plus gefitinib in



- patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. **Lancet Respir Med.** 2020 Nov;8(11):1132-1143.
11. **Yang JC\***, Schuler M, Popat S, Miura S, Heeke S, Park K, Märten A, Kim ES. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. **J Thorac Oncol.** 2020 May;15(5):803-815. (\*Corresponding author)
  12. **Yang JCH**, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. **J Clin Oncol.** 2020 Feb 20;38(6):538-547.
  13. **Yang JC\***, Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Hozak RR, Nguyen TS, Zhang WL, Enatsu S, Puri T, Orlando M. A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutation: Final Overall Survival and Biomarker Analysis. **J Thorac Oncol.** 2020 Jan;15(1):91-100. (\*Corresponding author)
  14. Lee CK, Man J, Lord S, Cooper W, Links M, GebSKI V, Herbst RS, Gralla RJ, Mok T. and **Yang JC.** Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. **JAMA Oncol.** 2018 Feb 1;4(2):210-216.
  15. Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, Bai YY, Huang D, Thress KS and **Yang JC\***. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. **Lancet Respir Med.** 2018 Feb;6(2):107-116. (\*Corresponding author)
  16. Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang ZF and **Yang JC\***. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. **Lancet Respir Med.** 2017 Nov;5(11):891-902. (\*Corresponding author)
  17. **Yang JC\***, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. **J Thorac Oncol.** 2017 Oct;12(10):1552-1560. (\*Corresponding author)
  18. **Yang JC\***, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. **J Clin Oncol.** 2017 Apr 20;35(12):1288-1296. (\*Corresponding author)
  19. Lee CK, Man J, Lord S, Links M, GebSKI V, Mok T, **Yang JC\*** Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. **J Thorac Oncol.** 2017 Feb;12(2):403-407. (brief report) (\*Corresponding author)
  20. **Yang JC**, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical Activity of Afatinib in Advanced NSCLC Harboring Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations: Combined Analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. **Lancet Oncol.** 2015 July;16(7): 830-838.
  21. **Yang JC\***, Wu YL\*, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V and Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. **Lancet Oncol.** 2015 Feb;16(2):141-151. (\*Corresponding author)
  22. Sequist LV, **Yang JC\***, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Pavlov SO, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M and Schuler M. Phase III



- 
- study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. **J Clin Oncol.** 2013 Sep 20;31(27):3327-3334. **(\*Corresponding author and equal contribution with first author)**.
23. **Yang JC\***, Hirsh V, Schuler M, Yamamoto N, O'Byrne K, Mok T, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Advanced Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Mutations. **J Clin Oncol.** 2013 Sep 20;31(27):3342-3350. **(\*Corresponding author)**
24. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu DT, Zaatar A, Sanchez J, Vu VV, Au JS, Inoue A, Lee SM, GebSKI V, **Yang JC\***. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. **J Natl Cancer Inst.** 2013 May 1;105(9):595-605. **(\*Corresponding author)**
25. Huang MH, Lee JH, Chang YJ, Tsai HH, Lin YL, Lin MY, **Yang JC\***. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. **Mol Oncol.** 2013 Feb; 7:112-120. **(\*Corresponding author)**
26. **Yang JC**, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. **Lancet Oncol.** 2012 May;13(5):539-548.
27. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, **Yang JC\***. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. **Lancet Oncol.** 2012 May;13(5):528-538. **(\*Corresponding author)**
-